StudyKIK Announces Industry First End-to-End Patient Recruitment Technology Platform to Sponsors and CROs: "End-to-End Study Management Platform"
New complete end-to-end study management platform which allows Sponsors and CROs to track all patient recruitment initiatives electronically in real time while having necessary data at their fingertips.
IRVINE, Calif., May 28, 2019 /PRNewswire-PRWeb/ -- StudyKIK, a patient recruitment and technology company that builds digital patient communities and patient communication technology solutions for sites and sponsors, announced the latest addition to their growing technology product line – the "End-to-End Study Management Platform." This new management platform will allow Sponsors and CROs to track all recruitment initiatives & sources electronically, including all vendors and media sources (and in real time), enabling them to hone their recruitment efforts on areas that will ultimately enroll more patients into their clinical trials.
The "End-to-End Study Management Platform" was created out of a need for transparency into where patients were sourced, what methods produced the highest yield of randomizations, and how to calculate ROI for patient recruitment. This information gap is primarily due to the lack integrations with study data systems - where patients' information is typically entered for confirming randomizations. StudyKIK has launched a proprietary method (through their technology platform) to integrate with these systems and match patient data behind the scenes, giving study teams a live dashboard with complete clarity into when and from what source patients are initially inquiring to being enrolled.
Additionally, with the support of StudyKIK's in-house GCP certified pre-screening team, Sponsor study teams now have the ability to track patient qualification and make real-time adjustments to their pre-screening questionnaires or protocols, based on where patients are disqualifying during the pre-screening process. Providing this level of insight has already saved significant time in the enrollment process for multiple pharmaceutical companies.
Stace Baal, Chief Technology Officer of StudyKIK stated,
"StudyKIK offers much more than just social media recruitment, but a full end-to-end study management technology platform that is focused on providing a level of clarity and data on enrollment not seen in the industry today. StudyKIK's goal with this is to speed up enrollment by allowing study teams to make educated patient recruitment decisions based on data for maximum patient exposure, ROI tracking, and to support sites with only quality referrals. We have designed this platform to be a resource any sponsor or CRO so they can implement to manage all trials within their organization all while allowing research sites to only have to log in to one portal for all patients."
With over 3,000 research sites using StudyKIK on a regular basis, sponsors that select StudyKIK as their "End-to-End Study Management Platform" will easily be able to start enrollment faster than ever before as there is no need to additional training on the platform. This portal also eliminates the burden of sites taking calls from multiple recruitment companies to get updates on which patients are randomized or screen failed, which puts less burden on the research site during central recruitment campaigns.
This complementary platform is already being used by many major pharmaceutical companies due to its easy-to-use interface, robust features, and ability to report on centrally run trials.
Since its inception, StudyKIK's goal is to provide an all-in-one solution that blends communication, tracking, and innovative technology to solve the needs of both research sites and study sponsors. With each new innovation, StudyKIK comes closer to accomplishing this goal and further solidifies itself as the largest patient & site centric recruitment company to service Pharmaceutical Companies, Contract Research Organizations in the industry.
More about StudyKIK:
StudyKIK is a patient recruitment and technology platform which was founded on patient communities on all major social media channels to increase awareness for clinical trials. Servicing over 3,000 research site users, StudyKIK owns hundreds of social media patient and caregiver communities across Instagram, Snapchat, Facebook, Twitter, and Pinterest to connect patients to clinical trials. They have addressed the clinical trial patient recruitment problem by building the technology solutions needed for research sites and pharmaceutical companies to access, manage, and communicate with high quality patients in real-time.
SOURCE StudyKIK
Share this article